Vancouver, British Columbia – May 17, 2016 – Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) (Xetra: ZSB) (the “Company”) is pleased to announce participation, in the form of presentations and exhibitions, in several global cosmetic industry conferences.
“Maintaining a strong presence in the global cosmetic industry is important as we continue to grow our pipeline and explore new areas of dermatology,” explained Attila Hajdu, Chief Business Development Officer of Sirona Biochem. “These conferences provide a great opportunity to conduct business with the key players in the industry in a timely and efficient manner.”
May 18-20: Attila Hajdu, Chief Business Development Officer of Sirona Biochem, will be exhibiting at China Beauty Expo in Shanghai and attending other business meetings in China and Korea. For more information on this conference, please visit: www.chinabeautyexpo.com/en
May 24-25: Dr. Geraldine Deliencourt-Godefroy, Chief Scientific Officer of Sirona Biochem, will present at COSM’innov 2016, the international congress on cosmetic science in Orléans France. CSOM’innov is where academia meets business as leading organizations seek the latest advances in the science of cosmetology. For more information on this conference, please visit: www.cosminnov.com
June 9-10: Attila Hajdu, Chief Business Development Officer of Sirona Biochem, will be presenting at the Innocos World Beauty Innovation Summit in Vienna, Austria. As a Gold Sponsor of the event, Sirona will have VIP access and dedicated 1:1 business meetings with senior executives from leading companies such as: Amore Pacific, Amway, Beiersdorf, Yves Rocher, Mirai Clinical, Sisley and Unilever. For more information on this conference, please visit: www.innocossummit.com
“As part of due diligence of a third party, our CRO performed additional safety and efficacy studies with our innovative skin lightening compound SBM-TFC-1067 in the last several weeks. The results are a major milestone that will significantly help us to close a licensing deal for this new compound in due course. Furthermore, it will provide scientific credibility enabling potential partners to initiate formulation and clinical trials required for approval of SBM-TFC-1067 in the major markets of the world (Japan, Korea, China, Europe and North America),” said Dr. Howard Verrico, CEO of Sirona Biochem.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant.
For more information please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.